This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?

Once a fast-growing pharmaceutical giant, Novo Nordisk (NYSE: NVO) has felt the effects of gravity over the past 18 months. The company's shares are down by more than 60% since early July 2024. One reason behind the company's terrible performance is that it has faced clinical setbacks for otherwise promising candidates within its core therapeutic area.The company recently announced yet another clinical failure -- this time, for its renowned compound, semaglutide, the active ingredient in medications such as Wegovy and Ozempic. Novo Nordisk's shares fell significantly -- by as much as 10% in one day -- following these developments, although they have recovered since. Is this bad news a good reason to finally give up on Novo Nordisk?Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool